PFE Pfizer Inc

$PFE Amazing that another unrelated drug company can have a drug failure and impact the whole industry.

$PFE Im enjoying the little pop at the end of each day's walk down. I think thats the stock giving us a little wink and nod

$PFE Low volume dump. Selling pressure running out. Bullish crossover today of the 50 over 200 and now day 6 of selling. Last time that happened (6 days consecutive), the stock went on a 2+ month run. Bought in @ 50% of position today. GLTA!

$PFE calm before the storm. looks like we are in good place, any news at this point should push this by 20%

$PFE showing some signs of strengths finally? We should see 30s again after 3 years ..I forgot how long I am in this lol

$PFE Pfizer and Valneva say their experimental Lyme disease vaccine reduced tick-borne infections by more than 70% in a late-stage trial of 9,400 people ages 5 and up, and the companies plan to submit the data to regulators despite the trial narrowly missing its statistical threshold for success, largely because Lyme disease cases were fewer than expected among participants. If approved, it would be the only Lyme vaccine on the market. LT

$PFE 28 and possibly 29 this coming week...AI freakout over anthropic delay and questions about ai regulation ...

$PFE Their BD team should be on the phone with every major AI lab, negotiating a drug discovery / production pipeline. Accelerate!

$PFE the correction we are beginning to see in PFE shares from an overvalued $29 makes perfect sense given the fundamentals do not warrant a valuation over $28 and much less warrant a valuation over 29 or $30. With interest rates rising the relative attractiveness of the dividend decreases and the patent cliffs are very very real. Elliquis , for example has contributed recently to earnings significantly but will lose patent protection and will be a huge $14 billion dollar revenue hit , it already has lost patent protection in Europe and generics have emerged there.

$PFE Pfizer (PFE) is much broader than its COVID business. Its portfolio spans oncology, inflammation & immunology, cardiovascular/metabolic disease, infectious diseases, rare diseases, and vaccines. Q1 2026 gives us a more encouraging signal: * Revenue excluding Comirnaty/Paxlovid: +7% operationally * Overall revenue: $14.5B * Eliquis: +13% * Oncology revenue: +9% * Padcev: +39% * Meanwhile, Comirnaty fell 59% and Paxlovid fell 62%. COVID is collapsing, yet the underlying Pfizer business is still growing. What you’re paying for Management’s 2026 guidance is: $59.5–62.5B revenue $2.80–$3.00 adjusted EPS At ~$27.65, that means you’re paying roughly: 9.2–9.9× 2026 adjusted earnings. That’s cheap for a major pharmaceutical company if Pfizer can stabilize earnings around $3/share and eventually grow again .

$PFE Board is back to normal, pumpers gone; endless misery commence🤣. All in all, it Could use a smidge of cooling off. Novartis wrecking the whole sector today not helping.

$PFE The market will rally after self imposed hardships are created and then repealed....you know the playbook....lots of coin will be made by those on the inside

$PFE There is a problem posting in Stocktwits! and they don't show! The posts also are not organised and show members posting with mixed dates! Is it only with me?

$PFE too many other stocks rippin, takin my loss and moving on, this sucker just cant get over 29

$PFE Debating on cashing out rest of profits from 24, before Trumpie crashes the markets ....again

$PFE read a well balanced article from simply wall st that stated that PFE is fully valued currently. That means the price already reflects potential good and has little to no upside from here , perhaps some modest downside. conclusion , at best a hold, definitely not a buy at these levels...............